Injection site reactions after dupilumab or tralokinumab for atopic dermatitis

Figures & data

Figure 1. Injection site reactions questionnaire.

Table 1. Baseline patient characteristics.

	Number of patients enrolled	Sex	Mean Age (years; mean ± SD)	Duration of AD (years; mean ± SD)	Atopic Comorbidities	Baseline Severity Scores (mean ± SD)
Dupilumab Group	327	190 (57%) males	50.2 ± 17.6	26.12 ± 10.6	Family history of AD:90/327 (27,5%)	EASI: 26.32 ± 8.43
					Asthma: 30/327 (9,2%)
		137 (43%) females			Allergic rhinitis: 60/327 (18;3%)	P-NRS: 8.22 ± 3.62
					Conjunctivitis:20/327 (6,12%)	DLQI: 24.09 ± 4.9
Tralokinumab Group	65	39 (60%) males	42.2 ± 15.4	21.03 ± 14.5	Family history of AD: 15/65 (23%)	EASI: 22.73 ± 10.61
					Asthma: 8/65 (12,3%)
		26 (40%) females			Allergic rhinitis:16,9%)	P-NRS: 8.76 ± 4.89
					Conjunctivitis:8/65 (12,3%)	DLQI: 22.23 ± 5.71

SD: standard deviation; AD: atopic dermatitis; EASI: Eczema Area Severity Index; P-NRS: Pruritus Numerical Rating Scale; DLQI: Dermatology Life Quality Index.

Figure 2. Injection site reactions (ISRs) in dupilumab group (n = 327 patients).

Figure 3. Injection site reactions (ISRs) in tralokinumab group (n = 65 patients).

Table 2. Results ISR and NRS value for both groups.

	ISR frequency	Mean NRS value pain/burning
Dupilumab Group	90/327 (27.52%)	4.9 ± 1.6.
Tralokinumab Group	39/65 (60%)	7.2 ± 2.3

*ISR: injection site reaction. NRS: Numerical Rating Scale.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.